Highest Mkt Cap
#8 of 49
$30 B
Highest CAGR
#6 of 49
28 %
Genetics and genomics are rapidly advancing fields in healthcare, with the potential to transform how diseases are diagnosed and treated. Advances in gene editing technologies like CRISPR have made it possible to edit and modify genes to treat genetic disorders, while genomic testing can be used to diagnose and predict the risk of diseases like cancer and Alzheimer's.
0 FDA approvals in Genetics and Genomics
Advancements in Genomics
"The cost of genome sequencing has decreased dramatically, from $100 million to around $1,000 today, making it more accessible than ever." - National Institutes of Health, February 2021
Personalized Medicine
"Genomics is the basis for personalized medicine... We can identify which drugs will work best for which patients, minimizing side effects and improving outcomes." - American Society of Human Genetics, January 2022
Understanding Disease
"Genetic testing can help us understand the underlying causes of diseases, leading to more targeted and effective treatments." - Genetics Home Reference, January 2023
Investor sentiment
MarketsandMarketsMay 2021
"...The global genetics and genomics market is expected to grow at a CAGR of over 10% during the forecast period 2021-2026, driven by the increasing adoption of genetics and genomics in for precision medicine, disease diagnosis, and drug discovery, and the growing need for personalized and targeted solutions."
ResearchAndMarketsJune 2021
"...The global genetics and genomics market is expected to reach $46.99 billion by 2027, driven by the increasing adoption of genetics and genomics in for precision medicine, disease diagnosis, and drug discovery, and the growing demand for cost-effective and accurate genomic tests."
Sector leaders
Color Genomics
Color Genomics uses genomic testing to provide personalized for people to proactively manage their health. Its testing services include inherited risk for cancer, heart disease, and other common conditions. The company raised $75 million in a recent Series D funding round to expand into international markets and expand its offerings to include whole-genome sequencing.
23andMe
23andMe provides direct-to-consumer genetic testing, allowing individuals to learn about their ancestry and genetic predispositions for certain conditions. The company has raised $791.1 million in funding, and has over 10 million customers. 23andMe has formed partnerships with numerous pharmaceutical companies, including GlaxoSmithKline, to develop new therapeutics and treatments.
